September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Spleen tyrosine kinase as a proto-oncogene in uveal melanoma
Author Affiliations & Notes
  • Luiza Neves
    Ophtalmology, Hospital Federal dos Servidores do Estado do RJ, Rio de Janeiro, Rio de Janeiro, Brazil
    The Henry C Witelson Ocular Pathology Laboratory, McGill University Health Center, Montreal, Quebec, Canada
  • Vinicius Lima
    The Henry C Witelson Ocular Pathology Laboratory, McGill University Health Center, Montreal, Quebec, Canada
  • Sultan Aldrees
    The Henry C Witelson Ocular Pathology Laboratory, McGill University Health Center, Montreal, Quebec, Canada
  • Jacqueline Coblentz
    The Henry C Witelson Ocular Pathology Laboratory, McGill University Health Center, Montreal, Quebec, Canada
  • Silvin Bakalian
    The Henry C Witelson Ocular Pathology Laboratory, McGill University Health Center, Montreal, Quebec, Canada
  • Miguel N Burnier
    The Henry C Witelson Ocular Pathology Laboratory, McGill University Health Center, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Luiza Neves, None; Vinicius Lima, None; Sultan Aldrees, None; Jacqueline Coblentz, None; Silvin Bakalian, None; Miguel Burnier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5902. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Luiza Neves, Vinicius Lima, Sultan Aldrees, Jacqueline Coblentz, Silvin Bakalian, Miguel N Burnier; Spleen tyrosine kinase as a proto-oncogene in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5902.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Spleen tyrosine kinase (Syk), a non-receptor tyrosine kinase, has been associated with cancer progression by acting as a proto-oncogene in some tumors, such as retinoblastoma, squamous cell carcinoma of the head and neck and naso-pharyngeal carcinoma. Conversely, Syk has been identified as a tumor suppressor in breast cancer, gastric cancer, and skin melanoma. The role of Syk in uveal melanoma (UM) has yet to be investigated. In this study, Syk expression in UM cells and in normal melanocytes was compared to further elucidate the role of Syk in UM.

Methods : Fifty-seven age matched eyes (23 UM and 34 normal human eyes [NHE]) were obtained from Henry C. Witelson Ocular Pathology Laboratory. Syk expression was analyzed using automated immunohistochemical staining and semiquantitatively evaluated using an immunoreactive score (IRS, 0-4). The IRS was calculated by the addition of staining intensity (0-2) and extension (0-2). Finally, the IRS was compared between normal choroidal melanocytes from normal human eyes and eyes containing UM, and also UM tumor cells. One-way analysis of variance (ANOVA) and Student’s t-test were used for statistical analysis.

Results : UM showed significantly higher IRS compared to normal melanocytes from UM eyes (P=0.0001) and also compared to normal melanocytes in NHE (P=0.001). No significant difference in Syk expression was identified between normal melanocytes from UM eyes and normal melanocytes from NHE.

Conclusions : In this study, higher expression of Syk in UM cells compared to normal melanocytes from eyes harboring UM and from NHE was demonstrated. These results may indicate that in UM Syk acts as an oncogene with higher expression in tumor cells. Finally, Syk may be a suitable target for new therapeutics in UM.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×